GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Allergan Plc (AGN) [hlAlert]

Rating:
Outperform
ACT
up 131.23 %

Actavis Inc. (WPI) rated Outperform by Leerink Swann

Posted on: Monday,  Jul 29, 2013  11:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Allergan Plc (NYSE: AGN) on 07/29/2013. Previously Leerink Swann rated Outperform Allergan Plc (NYSE: AGN) on
07/29/2013., when the stock price was $134.93. Since then, Allergan Plc has gained 131.23% as of 11/24/2015's recent price of $312.00.
If you would have followed the previous Leerink Swann 's recommendation on AGN, you would have gained 131.23% of your investment in 848 days.

Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacture, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2008, the Company marketed approximately 150 generic pharmaceutical product families and 27 brand pharmaceutical product families through its generic and brand divisions, respectively, and distributed approximately 8,000 stock-keeping units (SKUs) through its distribution division. The Company?s operations are based predominantly in the United States and India, with its key commercial market being the United States. In July 2008, Watson and Mylan Inc. announced that Mylan Inc. has acquired Watson?s 50% interest in the Somerset Pharmaceuticals, Inc. joint venture. In December 2009, the Company completed the acquisition of Arrow Group.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/29/2013 11:25 AM Buy
None
133.77
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/29/2013 8:25 AM Buy
None
134.93

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy